About Zoetis Inc.
https://www.zoetis.comZoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
CEO
Kristin C. Peck
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 887
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
BTIG
Buy
Argus Research
Buy
Morgan Stanley
Overweight
JP Morgan
Overweight
Piper Sandler
Overweight
Barclays
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:42.31M
Value:$5.32B
BLACKROCK INC.
Shares:36.84M
Value:$4.64B
BLACKROCK, INC.
Shares:36.2M
Value:$4.56B
Summary
Showing Top 3 of 2,346
About Zoetis Inc.
https://www.zoetis.comZoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.4B ▼ | $781M ▼ | $721M ▲ | 30.04% ▲ | $1.63 ▲ | $1.07B ▼ |
| Q2-2025 | $2.46B ▲ | $789M ▲ | $718M ▲ | 29.19% ▲ | $1.61 ▲ | $1.08B ▲ |
| Q1-2025 | $2.22B ▼ | $720M ▼ | $631M ▲ | 28.42% ▲ | $1.41 ▲ | $988M ▲ |
| Q4-2024 | $2.32B ▼ | $811M ▲ | $581M ▼ | 25.08% ▼ | $1.29 ▼ | $911M ▼ |
| Q3-2024 | $2.39B | $732M | $682M | 28.56% | $1.51 | $1.06B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.08B ▲ | $15.16B ▲ | $9.76B ▲ | $5.4B ▲ |
| Q2-2025 | $1.44B ▼ | $14.48B ▲ | $9.5B ▲ | $4.98B ▲ |
| Q1-2025 | $1.72B ▼ | $14.1B ▼ | $9.44B ▼ | $4.66B ▼ |
| Q4-2024 | $1.99B ▲ | $14.24B ▼ | $9.47B ▲ | $4.77B ▼ |
| Q3-2024 | $1.71B | $14.36B | $9.12B | $5.23B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $721M ▲ | $938M ▲ | $-160M ▲ | $-134M ▲ | $649M ▲ | $805M ▲ |
| Q2-2025 | $718M ▲ | $486M ▼ | $-247M ▼ | $-564M ▲ | $-286M ▼ | $308M ▼ |
| Q1-2025 | $631M ▲ | $587M ▼ | $-175M ▼ | $-677M ▲ | $-266M ▼ | $438M ▼ |
| Q4-2024 | $581M ▼ | $905M ▼ | $126M ▲ | $-745M ▼ | $273M ▲ | $689M ▼ |
| Q3-2024 | $692M | $951M | $-178M | $-628M | $140M | $784M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Cattle | $400.00M ▲ | $360.00M ▼ | $320.00M ▼ | $400.00M ▲ |
 Dogs and Cats | $-4230.00M ▲ | $1.48Bn ▲ | $1.72Bn ▲ | $1.59Bn ▼ |
 Fish | $70.00M ▲ | $50.00M ▼ | $70.00M ▲ | $80.00M ▲ |
 Horses | $5.80Bn ▲ | $70.00M ▼ | $70.00M ▲ | $70.00M ▲ |
 Poultry | $120.00M ▲ | $110.00M ▼ | $100.00M ▼ | $110.00M ▲ |
 Swine | $130.00M ▲ | $110.00M ▼ | $120.00M ▲ | $110.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 International Segment | $1.04Bn ▲ | $1.07Bn ▲ | $1.01Bn ▼ | $1.05Bn ▲ |
 United States Segment | $1.26Bn ▲ | $1.36Bn ▲ | $1.18Bn ▼ | $1.32Bn ▲ |
CEO
Kristin C. Peck
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 887
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
BTIG
Buy
Argus Research
Buy
Morgan Stanley
Overweight
JP Morgan
Overweight
Piper Sandler
Overweight
Barclays
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:42.31M
Value:$5.32B
BLACKROCK INC.
Shares:36.84M
Value:$4.64B
BLACKROCK, INC.
Shares:36.2M
Value:$4.56B
Summary
Showing Top 3 of 2,346